Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Exp Parasitol ; 192: 85-92, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30075233

ABSTRACT

Amphotericin B (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting, while the less toxic lipid-based formulations such as AmBisome® are very expensive. Two different strategies to improve the therapeutic index of AmB with inexpensive ingredients were evaluated on this work: (i) the heat treatment of the commercial formulation (H-AmB) and (ii) the preparation of an AmB-loaded microemulsion (ME-AmB). M-AmB was heated to 70 °C for 20 min. The resulting product was characterized by UV spectrophotometry and circular dichroism, showing super-aggregates formation. ME-AmB was prepared from phosphate buffer pH 7.4, Tween 80®, Lipoid S100® and Mygliol 812® with AmB at 5 mg/mL. The droplet size, measured by dynamic light scattering, was about 40 nm and transmission electron microscopy confirmed a spherical shape. Rheological analysis showed low viscosity and Newtonian behavior. All the formulations were active in vitro and in vivo against Leishmania donovani (LV9). A selectivity index (CC50 on RAW/IC50 on LV9) higher than 10 was observed for ME-AmB, H-AmB and AmBisome®. Furthermore, no important in vivo toxicity was observed for all the samples. The in-vivo efficacy of the formulations after IV administration was evaluated in Balb/C mice infected with LV9 (three doses of 1 mg/kg AmB) and no significant difference was observed between H-AmB, M-AmB, ME-AmB and AmBisome®. In conclusion, these two inexpensive alternative formulations for AmB showing good efficacy and selectivity for Leishmania donovani merit further investigation.


Subject(s)
Amphotericin B/pharmacology , Leishmania donovani/drug effects , Amphotericin B/chemistry , Amphotericin B/economics , Amphotericin B/toxicity , Animals , Circular Dichroism , Cricetinae , Emulsions , Female , Hot Temperature , Inhibitory Concentration 50 , Leishmania donovani/growth & development , Mice , Mice, Inbred BALB C , Microscopy, Electron, Transmission , RAW 264.7 Cells/drug effects , Rheology
2.
Int J Pharm ; 548(1): 276-287, 2018 Sep 05.
Article in English | MEDLINE | ID: mdl-29991450

ABSTRACT

Previous data from our research group showed that chitosan-coated poly(isobutylcyanoacrylate) nanoparticles (NPs) (denoted PIBCA/Chito20) exhibited intrinsic anti-Trichomonas vaginalis activity, while PIBCA/pluronic® F68 without chitosan (PIBCA/F68) were inactive. However, the mechanism of anti-T. vaginalis activity of chitosan-coated PIBCA NPs is still unknown. Our hypothesis is that chitosan-coated NPs are internalized by the parasite, contrarily to PIBCA/F68. In this investigation, the impact of NP surface on their internalization by the protozoan was studied using flow cytometry and parasite morphological changes after different incubation times with PIBCA/Chito20 NPs were monitored by electron microscopy. Flow-cytometry revealed that PIBCA/Chito20 NPs were uptaken by T. vaginalis as early as 10-min-incubation. Drastic cell morphological transformations were observed from scanning electron microscopy and transmission electron microscopy after incubation with PIBCA/Chito20 NPs. Numerous pits were seen on cell membrane since 10 min. Gradual increase in contact time increased NP endocytosis and induced proportional damages to T. vaginalis membrane. Then, investigation of whether PIBCA/Chito20 NPs can improve MTZ anti-T. vaginalis activity was studied using checkerboard experiment. Calculation of fractional inhibitory concentration index (FICI = 3.53) showed an additive effect between NPs and MTZ.


Subject(s)
Antiprotozoal Agents/administration & dosage , Cyanoacrylates/administration & dosage , Metronidazole/administration & dosage , Nanoparticles/administration & dosage , Trichomonas vaginalis/drug effects , Cell Membrane/drug effects , Cell Membrane/ultrastructure , Chitosan/administration & dosage , Enbucrilate , Endocytosis , Microscopy, Electron, Scanning , Microscopy, Electron, Transmission , Poloxamer/administration & dosage , Trichomonas vaginalis/ultrastructure
3.
Exp Parasitol ; 189: 72-75, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29730454

ABSTRACT

Metronidazole (MTZ) is a 5-nitroimidazole drug used for the treatment of Trichomonas vaginalis parasitic infection. Aqueous formulations containing MTZ are restricted because apparent solubility in water of this drug is low. In this context, two methylated-ß-cyclodextrins (CRYSMEB and RAMEB) were used as a tool to increase apparent solubility of MTZ in water. CRYSMEB was limited by its own solubility in water (15% w/w, 12.59 mM), while RAMEB at a concentration of 40% w/w (300.44 mM) allowed a maximal increase of apparent solubility of MTZ (3.426% w/w, 200.19 mM). From our knowledge, this corresponds to the highest enhancement of MTZ apparent aqueous solubility ever reported in the literature using methylated cyclodextrins. In vitro evaluations showed that anti-T. vaginalis activity of MTZ formulated with CRYSMEB and RAMEB was preserved.


Subject(s)
Antiprotozoal Agents/pharmacology , Metronidazole/pharmacology , Trichomonas vaginalis/drug effects , beta-Cyclodextrins/pharmacology , Antiprotozoal Agents/chemistry , Calibration , Chromatography, High Pressure Liquid , Crystallization , Female , Humans , Methylation , Metronidazole/chemistry , Sexually Transmitted Diseases/parasitology , Solubility , Trichomonas Vaginitis/parasitology , beta-Cyclodextrins/chemistry
4.
J Nanosci Nanotechnol ; 18(4): 2405-2414, 2018 Apr 01.
Article in English | MEDLINE | ID: mdl-29442909

ABSTRACT

While many naturally occurring polysaccharides have been widely used as drug carriers, there are two main drawbacks in their use: the first is their physical properties such as molecular weight, branching, type of glycosidic linkages and solubility depend on their source and the method of isolation and purification, the second is many of them are contaminated with proteins and protein removal is essential for preventing immune reactions. Synthetic polysaccharides on the other hand can be tailor made from their respective monomers with consistent physical properties and are, free from protein contamination, both being significant advantages in their use. Although, the synthesis of polysaccharides such as polyglucose, polymannose, polygalactose etc., by the polycondensation of their respective monomers have been reported more than half a century ago, their use as drug carriers have not received any attention so far. In this report, we show that polyglucose (PG) having a weight average molar mass of 37,000 g/mol can be synthesized in a single step by the melt polycondensation of glucose in over 70% yield. Oxidation using sodium periodate generated aldehyde functions on the polymer. Amphotericin B, (AmB) a water-insoluble polyene antibiotic was chosen as a model drug to couple onto periodate oxidized PG via imine linkage at ~20 wt% concentration. The drug loading capacity of the conjugates was above 90%. Further reduction using sodium borohydride gave the more stable amine conjugates with any residual aldehyde on the polymer backbone getting reduced to hydroxyl groups. The conjugates were highly soluble in water and stable on storage. At ten times the concentration of AmB, the conjugates produced negligible hemolysis to human blood. The AmB conjugates were then evaluated for their anti-fungal activity against C. albicans and A. fumigatus and anti-leishmanial activity against different strains of L. donovani in culture. The conjugates showed potent anti-fungal and anti-leishmanial activity. The use of synthetic polysaccharides in drug delivery and in other biomedical applications will have many potential advantages.


Subject(s)
Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Drug Carriers , Polysaccharides , Candida albicans , Glucans , Humans , Leishmaniasis/drug therapy
5.
Polymers (Basel) ; 10(2)2018 Feb 08.
Article in English | MEDLINE | ID: mdl-30966196

ABSTRACT

This study describes the design and characterization of a liposphere gel containing clotrimazole for the treatment of Candida albicans. Lipospheres were produced by the melt-dispersion technique, using a lipid phase constituted of stearic triglyceride in a mixture with caprylic/capric triglyceride or an alkyl lactate derivative. The latter component was added to improve the action of clotrimazole against candida. The liposphere morphology and dimensional distribution were evaluated by scanning electron microscopy. Clotrimazole release kinetics was investigated by an in vitro dialysis method. An anticandidal activity study was conducted on the lipospheres. To obtain formulations with suitable viscosity for vaginal application, the lipospheres were added to a xanthan gum gel. The rheological properties, spreadability, leakage, and adhesion of the liposphere gel were investigated. Clotrimazole encapsulation was always over 85% w/w. The anticandidal study demonstrated that the encapsulation of clotrimazole in lipospheres increased its activity against Candida albicans, especially in the presence of the alkyl lactate derivative in the liposphere matrix. A dialysis method demonstrated that clotrimazole was slowly released from the liposphere gel and that the alkyl lactate derivative further controlled clotrimazole release. Adhesion and leakage tests indicated a prolonged adhesion of the liposphere gel, suggesting its suitability for vaginal application.

6.
Clin Microbiol Rev ; 30(3): 811-825, 2017 07.
Article in English | MEDLINE | ID: mdl-28539504

ABSTRACT

The last estimated annual incidence of Trichomonas vaginalis worldwide exceeds that of chlamydia and gonorrhea combined. This critical review updates the state of the art on advances in T. vaginalis diagnostics and strategies for treatment and prevention of trichomoniasis. In particular, new data on treatment outcomes for topical administration of formulations are reviewed and discussed.


Subject(s)
Antiprotozoal Agents/therapeutic use , Trichomonas Infections/drug therapy , Trichomonas Infections/prevention & control , Administration, Topical , Antiprotozoal Agents/administration & dosage , Humans , Trichomonas Infections/diagnosis , Trichomonas vaginalis/physiology
7.
Pharm Res ; 34(5): 1067-1082, 2017 05.
Article in English | MEDLINE | ID: mdl-28168390

ABSTRACT

PURPOSE: The aim of this work is to design new chitosan conjugates able to self-organize in aqueous solution in the form of micrometer-size platelets. When mixed with amphotericin B deoxycholate (AmB-DOC), micro-platelets act as a drug booster allowing further improvement in AmB-DOC anti-Candida albicans activity. METHODS: Micro-platelets were obtained by mixing oleoyl chitosan and α-cyclodextrin in water. The formulation is specifically-engineered for mucosal application by dispersing chitosan micro-platelets into thermosensitive pluronic® F127 20 wt% hydrogel. RESULTS: The formulation completely cured C. albicans vaginal infection in mice and had a superior activity in comparison with AmB-DOC without addition of chitosan micro-platelets. In vitro studies showed that the platelets significantly enhance AmB-DOC antifungal activity since the IC50 and the MIC90 decrease 4.5 and 4.8-times. Calculation of fractional inhibitory concentration index (FICI = 0.198) showed that chitosan micro-platelets act in a synergistic way with AmB-DOC against C. albicans. No synergy is found between spherical nanoparticles composed poly(isobutylcyanoacrylate)/chitosan and AmB-DOC. CONCLUSION: These results demonstrate for the first time the ability of flattened chitosan micro-platelets to have synergistic activity with AmB-DOC against C. albicans candidiasis and highlight the importance of rheological and mucoadhesive behaviors of hydrogels in the efficacy of the treatment.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Blood Platelets/chemistry , Candida albicans/drug effects , Chitosan/pharmacology , Deoxycholic Acid/pharmacology , Amphotericin B/chemistry , Animals , Antifungal Agents/chemistry , Candidiasis/drug therapy , Chemistry, Pharmaceutical/methods , Chitosan/chemistry , Deoxycholic Acid/chemistry , Disease Models, Animal , Drug Combinations , Female , Hydrogels/chemistry , Hydrogels/pharmacology , Mice , Mice, Inbred BALB C , Mucous Membrane/drug effects , Nanoparticles/chemistry , Poloxamer/chemistry , Swine , alpha-Cyclodextrins/chemistry
8.
Int J Pharm ; 519(1-2): 381-389, 2017 Mar 15.
Article in English | MEDLINE | ID: mdl-28130196

ABSTRACT

This study reports design and evaluation of chitosan-based microparticle activity against Candida glabrata in vitro and in vivo in immunocompetent mice model artificially maintained in oestrus state. Because their flattened shape, chitosan microparticles are called here micro-platelets. They were obtained by self-association of oleoyl chitosan and α-cyclodextrin in water. A mixture of amphotericin B-deoxycholate (Fungizone®, AmB-DOC) and chitosan micro-platelets gelified with pluronic® F127 (20wt%) completely cured C. glabrata vaginal infection. Colony factor unit counting and mycological analysis of mice vaginal mucosa after Grocott-Gomori methenamine-silver staining confirmed the absence of C. glabrata. Furthermore, in vitro evaluations revealed that IC50 and MIC90 of AmB-DOC were decreased 1.8 and 1.4-times respectively when associated with chitosan micro-platelets. Neither native chitosan nor oleoyl chitosan allowed improvement in AmB-DOC anti-C. glabrata activity. This work demonstrates for the first time that a simple mixing of chitosan micro-platelets with AmB-DOC enhanced its anti-C. glabrata activity.


Subject(s)
Candida glabrata/drug effects , Chitosan/chemistry , Cyclodextrins/chemistry , Cyclodextrins/pharmacology , Immunocompromised Host/drug effects , Mucous Membrane/microbiology , Amphotericin B/chemistry , Amphotericin B/pharmacology , Animals , Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Candidiasis/drug therapy , Candidiasis/microbiology , Deoxycholic Acid/pharmacology , Drug Combinations , Mice
9.
Eur J Pharm Biopharm ; 112: 143-147, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27890510

ABSTRACT

The objective of this work is to design topically-applied thermosensitive and mucoadhesive hydrogel containing metronidazole (MTZ) for the treatment of Trichomonas vaginalis infections. Hydrogel composed of pluronic® F127 (20wt%), chitosan (1wt%) and metronidazole MTZ (0.7wt%) mixture showed its ability to decrease by a factor 4 MTZ flux and apparent permeability absorption through vaginal mucosa. The impact of hydrogel on transmucosal penetration of MTZ was evaluated ex vivo on excised porcine vaginal mucosa mounted on Franz diffusion cell. The anti-T. vaginalis activity of MTZ formulated into F127/chitosan hydrogel was preserved since the viability curve evaluated in vitro was similar to MTZ solution.


Subject(s)
Antiprotozoal Agents/pharmacokinetics , Chitosan/chemistry , Hydrogels/chemistry , Metronidazole/pharmacokinetics , Mucous Membrane/metabolism , Poloxamer/chemistry , Animals , Female , Permeability , Swine , Vagina
10.
Biomed Pharmacother ; 76: 127-33, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26653559

ABSTRACT

2-n-propylquinoline (2-n-PQ) had shown interesting in vivo antileishmanial activities after administration by oral route on leishmaniasis animal models. However, the lipophilic properties of this compound avoid its use by intravenous route, this route being indicated in cases of severe visceral leishmaniasis with vomiting. Thus, a 2-n-propylquinoline hydroxypropyl beta-cyclodextrin (2-n-PQ-HPC) formulation was set up in this aim. The formulation was active in vitro both on Leishmania donovani axenic and intramacrophage amastigotes with IC50 values at 6.22±0.82µM and 20.01±0.52µM, respectively, without any toxicity on macrophages. 2-n-PQ-HPC exhibited similar activity on WT and drug-resistant parasites. Its in vitro interactions with antimonials, amphotericin B and miltefosine were found as additive both in axenic amastigotes and intramacrophage amastigotes. 2-n-PQ-HPC was not able to generate drug resistance after in vitro drug pressure since the resistance index was less than 4. 2-n-PQ-HPC was also active on the L. donovani/Balb/c mice model with an intravenous treatment regimen at 10mgkg(-1)day(-1) on 10 consecutive days without hepatic, renal and blood toxicity. The pharmacokinetics of 2-n-PQ in rats showed that after an intravenous treatment of the formulation at 10mgkg(-1), the plasma drug concentrations rapidly declined bi-exponentially with a half-life of 58.7min and a total clearance of 18.63lh(-1)kg(-1). The apparent volume of distribution was higher than the blood volume in rats, indicating that 2-n-PQ was well distributed in tissues, allowing parasite elimination. Such a formulation is worth of further antiparasitic and toxicological evaluations.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmaniasis, Visceral/drug therapy , Quinolines/pharmacology , beta-Cyclodextrins/chemistry , 2-Hydroxypropyl-beta-cyclodextrin , Administration, Oral , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/chemistry , Disease Models, Animal , Drug Resistance , Drug Therapy, Combination , Female , Half-Life , Inhibitory Concentration 50 , Leishmania donovani/drug effects , Leishmaniasis, Visceral/parasitology , Male , Mice , Mice, Inbred BALB C , Quinolines/administration & dosage , Quinolines/chemistry , Rats , Rats, Sprague-Dawley , Tissue Distribution
11.
Fitoterapia ; 107: 100-104, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26463755

ABSTRACT

The two new acylphloroglucinol derivatives, methylene-bis-aspidinol AB (1) and mallopposinol (2), together with the nine known compounds, aspidinol B (3), methylene-bis-aspidinol (4), (+)-α-tocopherol (5), lupeol (6), stigmasterol (7), phytol (8), bergenin (9), squalene (11) and methyl gallate (10) were isolated from the leaves of Mallotus oppositifolius. Their structures were elucidated by spectral analysis including MS, 1D and 2D-NMR spectroscopy. In vitro trypanocidal and antileishmanial activities of compounds 1-9 were evaluated. Mallopposinol (2) and aspidinol B (3) displayed weak antileishmanial activities against Leishmania donovani promastigotes, with EC50 values of 21.3 and 38.8µM, respectively. Only the methylene-bis-aspidinol (4) exhibited trypanocidal activity against Trypanosoma brucei brucei trypomastigotes (LC100=0.8µM) similar to the reference drug pentamidine (LC100=0.4µM).


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania donovani/drug effects , Mallotus Plant/chemistry , Phloroglucinol/pharmacology , Trypanosoma brucei brucei/drug effects , Antiprotozoal Agents/isolation & purification , Inhibitory Concentration 50 , Molecular Structure , Phloroglucinol/isolation & purification , Plant Extracts/chemistry , Plant Leaves/chemistry
12.
Pharm Res ; 32(4): 1229-36, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25319099

ABSTRACT

PURPOSE: The present work reports a non-conventional therapeutic strategy based on the use of vaginally-applied formulations for the treatment of trichomoniasis due to Trichomonas vaginalis without adding a drug. METHODS: The formulations were based on a thermosensitive pluronic® F127 hydrogel containing mucoadhesive poly(isobutylcyanoacrylate) nanoparticles coated with a mixture of chitosan and thiolated chitosan (75/25 wt%). The nanoparticles were obtained by anionic emulsion polymerization of isobutylcyanoacrylate. The anti-T. vaginalis activity of the formulations was evaluated in vitro. RESULTS: Chitosan-coated nanoparticles showed a strong anti-T. vaginalis activity at 100 µg/mL independently on the proportion of thiolated chitosan. No anti-T. vaginalis activity was reported neither with chitosan-uncoated poly(isobutylcyanoacrylate) nanoparticles nor with chitosan used as a solution. These results suggest that the anti-T. vaginalis activity was related to poly(isobutylcyanoacrylate) nanoparticles but only when they are coated with chitosan. Histological analysis of ex vivo pig vaginal mucosa in contact with pluronic® F127 hydrogel containing poly(isobutylcyanoacrylate) nanoparticles coated with the mixture chitosan/thiolated chitosan (75/25 wt%) did not reveal any toxicity. CONCLUSION: This study demonstrated that poly(isobutylcyanoacrylate) nanoparticles coated with chitosan were active against T. vaginalis without adding a drug. Besides their anti-T. vaginalis activity, the formulations are non-toxic towards pig vaginal mucosa.


Subject(s)
Antiprotozoal Agents/pharmacology , Chitosan/chemistry , Cyanoacrylates/pharmacology , Mucous Membrane/drug effects , Nanoparticles/chemistry , Trichomonas vaginalis/drug effects , Vagina/drug effects , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/toxicity , Cyanoacrylates/administration & dosage , Cyanoacrylates/toxicity , Drug Carriers/chemistry , Enbucrilate , Female , In Vitro Techniques , Parasitic Sensitivity Tests , Swine , Tissue Adhesives/chemistry , Trichomonas vaginalis/growth & development
13.
ChemMedChem ; 10(2): 411-8, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25523035

ABSTRACT

Curcumin, a natural polyphenolic compound, showed antiparasitic potential, including trypanocidal and leishmanicidal activity, in several in vitro and in vivo models. The molecule is well tolerated in humans. However, it is insoluble in water and displays poor oral bioavailability as a result of low absorption. New derivatives of curcumin were prepared by esterification of one or two of its phenolic groups with 1,1',2-tris-norsqualenic acid. These "squalenoylcurcumins" were formulated as water-dispersible nanoassemblies of homogeneous size, and they proved to be stable. Squalenoylcurcumins were inactive against Trypanosoma brucei brucei trypomastigotes, even as nanoassemblies, in contrast with curcumin. However, against Leishmania donovani promastigotes, the activities of the squalenoylcurcumins and their nanoassemblies were enhanced relative to that of curcumin. In L. donovani axenic and intramacrophagic amastigotes, they showed activity in the range of miltefosine, with good selectivity indexes. In regard to their dispersibility in water and to the safety of curcumin, these nanoassemblies are promising candidates for preclinical study toward the treatment of visceral leishmaniasis.


Subject(s)
Antiprotozoal Agents/chemistry , Curcumin/chemistry , Nanoparticles/chemistry , Animals , Antiprotozoal Agents/pharmacology , Cell Line , Cell Survival/drug effects , Curcumin/pharmacology , Esterification , Leishmania donovani/drug effects , Mice , Trypanosoma brucei brucei/drug effects , Water/chemistry
14.
Molecules ; 19(4): 4200-11, 2014 Apr 03.
Article in English | MEDLINE | ID: mdl-24705564

ABSTRACT

With at least 60% of the Millettia species (Fabaceae) being in medicinal use, we found it relevant to assess the potential antiprotozoal and antifungal activities of Millettia richardiana. Water and methanol crude extracts of the stem barks from M. richardiana and the six fractions resulting from the fractionation of the methanol extract were tested. The dichloromethane extracted fraction showed the best in vitro antiprotozoal activities (IC50=5.8 µg/mL against Plasmodium falciparum, 11.8 µg/mL against Leishmania donovani and 12.8 µg/mL against Trypanosoma brucei brucei) as well as low cytotoxicity on several cell lines. The phytochemical analysis showed this selected fraction to be rich in terpenoids and alkaloids, which could explain its antiparasitic activity. A phytochemical study revealed the presence of lonchocarpenin, betulinic acid, ß-amyrin, lupeol, palmitic acid, linoleic acid and stearic acid, among which betulinic acid and lupeol could be the compounds responsible of these antiprotozoal activities. By contrast, neither the crude extracts nor the fractions showed antifungal activity against Candida. These results confirm the importance of the genus Millettia in Malagasy ethnomedicine, its potential use in antiparasitic therapy, and the interest of developing a sustainable exploitation of this plant. Moreover, both molecules betulinic acid and lupeol appeared as very relevant molecules for their antiprotozoal properties.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania donovani/drug effects , Millettia/chemistry , Plant Extracts/pharmacology , Plasmodium falciparum/drug effects , Trypanosoma brucei brucei/drug effects , Alkaloids/isolation & purification , Antiprotozoal Agents/chemistry , Leishmania donovani/growth & development , Madagascar , Methanol , Methylene Chloride , Plant Bark/chemistry , Plant Extracts/chemistry , Plant Stems/chemistry , Plasmodium falciparum/growth & development , Solvents , Terpenes/isolation & purification , Trypanosoma brucei brucei/growth & development
15.
Int J Pharm ; 454(2): 695-702, 2013 Oct 01.
Article in English | MEDLINE | ID: mdl-23792467

ABSTRACT

The aim of the present work is to design a new formulation containing clotrimazole (CTZ) loaded into nanostructured lipid carriers (NLC) for the treatment of fungal vaginal infections. In order to obtain formulations with suitable viscosity for mucosal application, NLC containing CTZ produced by the ultrasonication method were viscosized by the addition of poloxamer P407 in the NLC dispersion (CTZ-NLC-gel). These systems exhibit well-known thermogelling properties. The rheological characterization of the CTZ-NLC hydrogel using a controlled stress rheometer evidenced that the presence of NLC or CTZ did not affect gelling temperature (Tgel). Dilution with simulated vaginal fluid (SVF) increased the Tgel from 17.4 to 29.6°C. For these thermogelling systems, micro-calorimetric assays conducted by a Micro-DSC III confirmed that the hydrogel-containing CTZ-NLC was able to change its structure with a rapid passage from non-crystalline (liquid) to crystalline (semi-solid) form. Furthermore, when a local application is considered, no drug should pass through the vaginal mucosa, limiting thus the systemic diffusion and toxicity. For this purpose, Franz cell has been employed to investigate the ex vivo permeation of CTZ through pig vaginal mucosa. The results showed no CTZ diffusion. The toxicological experiments performed on HeLa cells after a 24h incubation time confirmed that CTZ-NLC-gel at a concentration of 1mg/mL showed a low toxicity profile resulting in a cell vitality of 77.2%. Interestingly, anti-candida activity studies demonstrated that CTZ-NLC gel was 4-fold more active than Fungizone(®) against Candida albicans. These encouraging results suggest that the hydrogel containing CTZ-NLC could be proposed as an innovative system to administer CTZ to treat vaginal infections.


Subject(s)
Antifungal Agents/chemistry , Clotrimazole/chemistry , Drug Carriers/chemistry , Nanostructures/chemistry , Animals , Antifungal Agents/administration & dosage , Candida albicans/drug effects , Cell Survival/drug effects , Clotrimazole/administration & dosage , Drug Carriers/administration & dosage , Female , HeLa Cells , Hot Temperature , Humans , Hydrogels , In Vitro Techniques , Lipids/chemistry , Microbial Sensitivity Tests , Mucous Membrane/metabolism , Nanostructures/administration & dosage , Poloxamer/chemistry , Swine , Vagina/metabolism
16.
Planta Med ; 78(16): 1777-9, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22948611

ABSTRACT

Two new unusual 6-furanoflavones, hoslunfuranine (5) and 5-O-methylhoslunfuranine (6), were isolated from the leaves of Hoslundia opposita Vahl.. Four known methylpyranoflavonic analogues [hosloppin (1), hoslundin (2), 5-O-methylhoslundin (3), oppositin (4)], all specific of the species, were also obtained. Their structures were established on the basis of their spectroscopic data. In vitro cytotoxic, trypanocidal, and leishmanicidal activities of compounds 1 and 3 to 6 were evaluated. Compounds 4 and 6 exhibited leishmanicidal potential in the micromolar range.


Subject(s)
Flavones/pharmacology , Lamiaceae/chemistry , Plant Leaves/chemistry , Pyrones/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/isolation & purification , Antiprotozoal Agents/pharmacology , Drug Screening Assays, Antitumor , Flavones/chemistry , Flavones/isolation & purification , Humans , KB Cells , Leishmania donovani/drug effects , Magnetic Resonance Spectroscopy , Parasitic Sensitivity Tests , Pyrones/chemistry , Pyrones/isolation & purification , Trypanosoma brucei brucei/drug effects
17.
Int J Pharm ; 436(1-2): 106-10, 2012 Oct 15.
Article in English | MEDLINE | ID: mdl-22814222

ABSTRACT

To predict the efficacy and toxicity of pulmonary administration of liposomal amphotericin B (L-AMB) for the treatment or the prevention of pulmonary invasive aspergillosis, a multistage liquid impinger was used to estimate the concentrations of drug that could be attained in different lung compartments after nebulization. The highest concentration of amphotericin B was found in the alveolar compartment, where it was calculated that the concentration in the lung surfactant could reach 54 µM or more when 21.6 µmoles of drug as liposomes was nebulized. The uptake and toxicity of L-AMB were studied in vitro using the A549 human lung epithelial cell line. Uptake was time and concentration-dependent and reached intracellular concentrations exceeding the minimal inhibitory concentrations for most Aspergillus species. The toxicity of L-AMB toward these cells, estimated by the MTT reduction assay, was reduced compared with the conventional form, deoxycholate amphotericin B (D-AMB), with an IC(50) value of about 120 µM after 24 h of exposure for D-AMB, but only a 13% reduction in viability for 200 µM L-AMB at 24 h. These results indicate that aerosol therapy with nebulized L-AMB could be efficient but that doses need to be carefully controlled to avoid toxicity.


Subject(s)
Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Administration, Inhalation , Aerosols , Amphotericin B/metabolism , Amphotericin B/toxicity , Antifungal Agents/metabolism , Antifungal Agents/toxicity , Biological Transport , Cell Line, Tumor , Cell Survival/drug effects , Humans , Liposomes , Nebulizers and Vaporizers
18.
Eur J Med Chem ; 52: 44-50, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22472166

ABSTRACT

A new family of quinolinone derivatives has been synthesized and evaluated for their antikinetoplastid activities against Leishmania donovani and Trypanosoma brucei brucei. Results from these structure-activity relationship studies enabled identification of compounds 3a and 4g as the most active compounds against L. donovani promastigotes and amastigotes parasites (IC(50) values in a range of 2-11 µM). Additionally, compound 3b has emerged from this study as the most active compound in the series against T. b. brucei with a MEC value of 12 µM. These three compounds are worth of further in vivo evaluation.


Subject(s)
Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/pharmacology , Leishmania donovani/drug effects , Quinolones/chemical synthesis , Quinolones/pharmacology , Trypanosoma brucei brucei/drug effects , Animals , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/toxicity , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Design , Mice , Quinolones/chemistry , Quinolones/toxicity , Structure-Activity Relationship
20.
Chem Biodivers ; 8(4): 658-67, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21480511

ABSTRACT

The essential oil from the rhizomes of Aframomum sceptrum (Zingiberaceae) was analyzed by GC/MS, and its major constituents were found to be ß-pinene (12.7%), caryophyllene oxide (10.0%), and cyperene (6.0%). The oil was also evaluated for antimicrobial activities, in comparison with ß-pinene, caryophyllene oxide, and the leaf essential oil of Melaleuca alternifolia (Myrtaceae). The A. sceptrum essential oil exhibited bacteriostatic activity against the Gram-positive bacteria Bacillus subtilis, Staphylococcus epidermidis, and S. aureus, but not against Gram-negative bacteria. Moreover, it showed mild fungicidal activity against Candida albicans and Aspergillus fumigates, and remarkable antiprotozoal activity against Trypanosoma brucei brucei (MLC of 1.51 µl/ml) and Trichomonas vaginalis (IC(50) of 0.12±0.02 and MLC of 1.72 µl/ml).


Subject(s)
Anti-Infective Agents/chemistry , Anti-Infective Agents/pharmacology , Antiprotozoal Agents/chemistry , Antiprotozoal Agents/pharmacology , Oils, Volatile/chemistry , Oils, Volatile/pharmacology , Zingiberaceae/chemistry , Animals , Anti-Infective Agents/isolation & purification , Antiprotozoal Agents/isolation & purification , Bacteria/drug effects , Bacterial Infections/drug therapy , Bicyclic Monoterpenes , Bridged Bicyclo Compounds/chemistry , Bridged Bicyclo Compounds/isolation & purification , Bridged Bicyclo Compounds/pharmacology , Cattle , Fungi/drug effects , Gas Chromatography-Mass Spectrometry , Humans , Monoterpenes/chemistry , Monoterpenes/isolation & purification , Monoterpenes/pharmacology , Mycoses/drug therapy , Oils, Volatile/isolation & purification , Plant Oils/chemistry , Plant Oils/isolation & purification , Plant Oils/pharmacology , Polycyclic Sesquiterpenes , Rhizome/chemistry , Sesquiterpenes/chemistry , Sesquiterpenes/isolation & purification , Sesquiterpenes/pharmacology , Trypanosoma brucei brucei/drug effects , Trypanosomiasis, Bovine/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...